Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma-Reference-Cited by-同舟云学术

Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma

Published:2019-01-21 Issue:4 Volume:68 Page:553-561
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Abu-Sbeih Hamzah,Ali Faisal S.,Qiao Wei,Lu Yang,Patel Sapna,Diab Adi,Wang Yinghong^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-019-02303-1/fulltext.html

Reference38 articles.

1. Abu-Sbeih H et al (2018) Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. J Immunother Cancer 6(Suppl 1):P537

2. Ribas A et al (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315(15):1600–1609

3. Wolchok JD et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345–1356

4. Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2(10):1346–1353

5. Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case of immune checkpoint inhibitor-associated colitis treated with infliximab;Okayama Igakkai Zasshi (Journal of Okayama Medical Association);2024-08-01

2. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events;Frontiers in Immunology;2024-06-10

3. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-04

4. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología (English Edition);2024-04